Last reviewed · How we verify

osimertinib oral and bevazizumab intravenously

Qingdao Central Hospital · Phase 3 active Small molecule

osimertinib oral and bevazizumab intravenously is a Small molecule drug developed by Qingdao Central Hospital. It is currently in Phase 3 development. Also known as: bevacizumab, osimertinib.

At a glance

Generic nameosimertinib oral and bevazizumab intravenously
Also known asbevacizumab, osimertinib
SponsorQingdao Central Hospital
ModalitySmall molecule
PhasePhase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about osimertinib oral and bevazizumab intravenously

What is osimertinib oral and bevazizumab intravenously?

osimertinib oral and bevazizumab intravenously is a Small molecule drug developed by Qingdao Central Hospital.

Who makes osimertinib oral and bevazizumab intravenously?

osimertinib oral and bevazizumab intravenously is developed by Qingdao Central Hospital (see full Qingdao Central Hospital pipeline at /company/qingdao-central-hospital).

Is osimertinib oral and bevazizumab intravenously also known as anything else?

osimertinib oral and bevazizumab intravenously is also known as bevacizumab, osimertinib.

What development phase is osimertinib oral and bevazizumab intravenously in?

osimertinib oral and bevazizumab intravenously is in Phase 3.

Related